A Phase I, open-label, single-dose pharmacokinetic study of IPP-201101 after subcutaneous and intravenous administration in healthy male volunteers
Latest Information Update: 28 Sep 2023
At a glance
- Drugs Forigerimod (Primary) ; Forigerimod
- Indications Asthma; Chronic inflammatory demyelinating polyradiculoneuropathy; Gout; Periodontitis; Polyradiculoneuropathy; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors ImmuPharma
Most Recent Events
- 28 Sep 2023 New trial record